Market newbie Kendrick Resources (KEN), a mineral exploration and development company, said it has exercised its option to conditionally acquire the Espedalen, Hosanger, and Sigdal nickel-copper-cobalt exploration projects in Norway
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept (“POC”) for its
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection includes Berkeley, Bluerock, Cloudbreak, 4D, Egdon, Hemogenyx, Igas, Neometals,
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration (“FDA”) that the proposed pre-Investigational
Yesterday saw a decent rebound in shares of Eurasia Mining (EUA), as the palladium, platinum, rhodium, iridium and gold producing company, announced that Eurasia has incorporated a 100% beneficially owned
A company which some in the market are suggesting could be bigger than Greatland Gold (GGP), Artemis Resources (ARV), said that exploration drilling has commenced at the Chapman Discovery, part
Haydale (HAYD), the advanced materials group, has been awarded a SMARTCymru grant from The Welsh Government that will enable the Ammanford-based company to progress with the development of its anti-counterfeiting
Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.
Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company (“Janus”) for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the “Agreement”) with the global biopharmaceutical
